

09 PH  
F 179.



**GENE EXPRESSION OF  
NERVE GROWTH FACTOR IN THE  
DEVELOPING  
SPONTANEOUSLY HYPERTENSIVE RAT**

A Thesis submitted to the University of Adelaide in fulfilment of the requirements for  
the degree of

**Doctor of Philosophy**

*in*

The Department of Clinical and Experimental Pharmacology, University of Adelaide

*by*

**Patrick Helmer James Falckh B.Sc.(Hons.)**

February 1992

## ABSTRACT

Hypernoradrenergic innervation of the vasculature is a recognised as a key characteristic in the spontaneously hypertensive rat (SHR), a genetic animal model of hypertension. Nerve growth factor (NGF), a protein essential for the development and maintenance of sympathetic innervation, has been shown to be elevated in the young SHR when compared to the normotensive control, the Wistar-Kyoto (WKY) rat. NGF concentrations have been shown to correlate with gene expression for the protein and with the degree of sympathetic innervation in many species. The NGFmRNA levels in cardiovascular tissue of neonatal, and developing, SHR and WKY rats were investigated to determine if there is a link between the gene expression of NGF and the pattern of abnormal sympathetic innervation in this model.

The reliability of the cDNA probe used for the determination of NGFmRNA concentrations was initially verified by investigating NGFmRNA concentrations in the submaxillary salivary gland of the mouse after pharmacological manipulation.

Mesenteric and caudal arteries of the SHR were found to contain significantly elevated levels of NGFmRNA (> 5 fold) consistent with the hypernoradrenergic state reported for these blood vessels. The kidney of the SHR also displayed an elevated NGFmRNA production, consistent with the elevated innervation reported for this tissue. Cardiac and aortic tissues, which do not exhibit hypernoradrenergic innervation in the SHR, displayed low levels of NGFmRNA which were generally similar to levels seen in cardiac and aortic tissues from WKY rats. In the hypernoradrenergically

innervated tissues the NGFmRNA levels were elevated as early as 2 days of age and the elevated level sustained for 6 weeks. The latter period corresponds to the normal time course for sympathetic innervation of the vasculature.

It is proposed that the elevated degree of innervation seen in resistance vessels and organs (for example in the kidney) is due, in part, to a sustained elevation of NGFmRNA and that the elevated NGFmRNA is present at birth. The findings also provide a rational basis for the elevated noradrenaline (NA) content of vessels in the SHR, the larger releasable pool of NA in the SHR and the elevated levels of NGF peptide in vessels from the SHR. The results provide sufficient stimulus for examination of a role of NGF in the initiation of hypertension in the SHR.

# CONTENTS

DECLARATION	i
LIST OF PUBLICATIONS IN SUPPORT	ii
ACKNOWLEDGMENTS	iii
ABSTRACT	iv
ABBREVIATIONS	vi
CONTENTS	x

## CHAPTER I : GENERAL INTRODUCTION 1

<b>I.1 Hypertension</b>	1
I.1.1 <i>Definition</i>	1
I.1.2 <i>Aetiology of Essential Hypertension</i>	4
I.1.3 <i>Genetic Hypertension</i>	5
I.1.4 <i>Sympathetic Nervous System</i>	6
I.1.5 <i>Structural Changes</i>	13
<b>I.2 Animal Models of Hypertension</b>	15
I.2.1 <i>Spontaneously Hypertensive Rat</i>	16
I.2.1.1 <i>Hypernoradrenergic Innervation</i>	19
I.2.1.2 <i>Structural Changes</i>	23
<b>I.3 Nerve Growth Factor</b>	25
<b>I.4 Introduction Summary</b>	35
<b>I.5 Aims</b>	36

<b>CHAPTER II : GENERAL METHODS</b>	<b>37</b>
<b>II.1 Glassware and Solutions</b>	<b>37</b>
<b>II.2 Gel Electrophoresis</b>	<b>37</b>
II.2.1 <i>Equipment</i>	38
II.2.2 <i>RNA Electrophoresis</i>	38
II.2.2.1 <i>Buffers</i>	39
II.2.2.2 <i>Gel Preparation</i>	39
II.2.2.3 <i>Sample Preparations</i>	40
II.2.2.4 <i>Visualisation</i>	40
II.2.3 <i>DNA Electrophoresis</i>	43
II.2.3.1 <i>Buffers</i>	43
II.2.3.2 <i>Gel Preparation</i>	43
II.2.3.3 <i>Sample Preparation</i>	44
II.2.3.4 <i>Visualisation</i>	44
<b>II.3 Northern Transfers</b>	<b>45</b>
<b>II.4 Slot Blots</b>	<b>45</b>
II.4.1 <i>Sample Preparation</i>	46
II.4.2 <i>Sample Application</i>	46
<b>II.5 The cDNA Probe</b>	<b>47</b>
II.5.1 <i>NGFmRNA Probe Production</i>	47
<b>II.6 Radiolabelling of the cDNA Probe</b>	<b>52</b>
II.6.1 <i>Nick Translation</i>	52
<b>II.7 Hybridisation of Nitrocellulose Filters</b>	<b>56</b>
II.7.1 <i>Prehybridisation</i>	56
II.7.2 <i>Hybridisation</i>	57
II.7.3 <i>Stringency Washes</i>	59
<b>II.8 Autoradiography</b>	<b>59</b>
<b>II.9 DNA Determinations</b>	<b>60</b>
<b>II.10 Protein Determinations</b>	<b>60</b>

<b>CHAPTER III : ISOLATION OF RNA USING GUANIDINIUM- PHENOL-CHLOROFORM METHODOLOGIES</b>	<b>62</b>
<b>III.1 Introduction</b>	<b>62</b>
<b>III.2 Isolation of RNA</b>	<b>63</b>
III.2.1 <i>The Chomczynski-Sacchi Method</i>	63
III.2.1.1 <i>Reagents</i>	64
III.2.1.2 <i>Small Scale Homogenisations</i>	64
III.2.1.3 <i>Large Scale Homogenisation</i>	65
III.2.1.4 <i>RNA Extraction</i>	65
III.2.1.5 <i>Purity</i>	66
III.2.2 <i>The Combined Phenol Method</i>	67
III.2.2.1 <i>Homogenisation Solution</i>	69
III.2.2.2 <i>RNA Extraction</i>	69
III.2.2.3 <i>Purity</i>	70
 <b>CHAPTER IV : CHANGES IN NGFmRNA AND NGF BY ANDROGEN MANIPULATION</b>	 <b>73</b>
<b>IV.1 Introduction</b>	<b>73</b>
<b>IV.2 Methods</b>	<b>75</b>
IV.2.1 <i>Animals and Tissue Collection</i>	75
IV.2.2 <i>RNA Analysis</i>	76
IV.2.2.1 <i>Northern Transfer</i>	76
IV.2.2.2 <i>Slot Blots</i>	76
IV.2.2.3 <i>Hybridisation</i>	77
IV.2.3 <i>NGF Analysis</i>	77
IV.2.4 <i>Statistical Analysis</i>	78
<b>IV.3 Results</b>	<b>78</b>
IV.3.1 <i>Body and Tissue Weights</i>	78
IV.3.2 <i>Extraction and NGFmRNA Content</i>	79
IV.3.3 <i>NGF Determinations</i>	81
<b>IV.4 Discussion</b>	<b>85</b>

<b>CHAPTER V : EXPRESSION OF NGF IN THE HEART AND KIDNEY IN THE DEVELOPING SHR</b>	<b>88</b>
<b>V.1 Introduction</b>	<b>88</b>
<b>V.II Methods</b>	<b>89</b>
V.II.1 <i>Animals and Tissue Removal</i>	89
V.II.2 <i>RNA Isolation and Application to Nitrocellulose membranes</i>	90
V.II.3 <i>Hybridisation of Filters</i>	90
V.II.4 <i>Autoradiography</i>	91
V.II.5 <i>Statistical Significance</i>	91
<b>V.III Results</b>	<b>92</b>
<b>V.IV Discussion</b>	<b>99</b>
 <b>CHAPTER VI : EXPRESSION OF NGF IN RESISTANCE VESSELS IN THE DEVELOPING SHR</b>	 <b>102</b>
<b>VI.1 Introduction</b>	<b>102</b>
<b>VI.2 Methods</b>	<b>103</b>
VI.2.1 <i>Animals and Tissue Removal</i>	103
VI.2.2 <i>RNA Isolation</i>	104
VI.2.3 <i>Northern Blot</i>	104
VI.2.4 <i>Slot Blots</i>	105
VI.2.5 <i>Hybridisation</i>	105
VI.2.6 <i>Statistical Significance</i>	106
<b>VI.3 Results</b>	<b>106</b>
<b>VI.4 Discussion</b>	<b>114</b>

<b>CHAPTER VII : TISSUE NORADRENALINE CONTENT IN MALE AND FEMALE F1 HYBRID RATS</b>	<b>120</b>
<b>VII.1 Introduction</b>	<b>120</b>
<b>VII.2 Methods</b>	<b>122</b>
VII.2.1 <i>Animals</i>	122
VII.2.2 <i>BP Analysis</i>	122
VII.2.3 <i>Tissue Collection</i>	123
VII.2.4 <i>Catecholamine Analysis</i>	123
VII.2.5 <i>Statistical Analysis</i>	124
<b>VII.3 Results</b>	<b>125</b>
<b>VII.4 Discussion</b>	<b>129</b>
 <b>CHAPTER VIII : GENERAL CONCLUSIONS</b>	 <b>133</b>
 <b>BIBLIOGRAPHY</b>	 <b>141</b>
 <b>APPENDICES</b>	 <b>166</b>